NEW YORK, June 11 – Canada’s Virtek Vision International said Monday that its Virtek ChipWriter and Virtek ChipReader had been selected for a six-month trial to apply its microarray technology for a neonatal screening application.

Under the terms of the alliance, Virtek has agreed to supply its spotter and reader to Neo Gen Screening and TeleChem International/ArrayIt.com for the testing of metabolic disorders in newborns. TeleChem of Sunnyvale, Calif., has developed the assays while Neo Gen Screening of Pittsburgh, Pa., develops tests for screening disorders.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Thermo Fisher Scientific says it will no longer sell machines in China's Xinjiang region, according to the Wall Street Journal.

New Scientist reports that 20 percent of human and yeast proteins are uncharacterized.

The University of Zurich's Ruedi Aebersold and his colleagues analyzed a dozen HeLa cell lines to find differences in gene expression, protein levels, and more.

In Nature this week: protein-coding variants associated with body-fat distribution, and more.